Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Orexo AB ( (SE:ORX) ) just unveiled an update.
Orexo AB’s annual general meeting on May 8, 2025, resulted in the re-election of its board members and auditor, Ernst & Young Aktiebolag. The meeting also approved several key resolutions, including the authorization to issue new shares and repurchase own shares, aimed at enhancing corporate flexibility and capital usage. Additionally, the company adopted new articles of association to allow postal voting and the issuance of class C shares, reflecting strategic measures to strengthen its market position and shareholder engagement.
More about Orexo AB
Orexo AB is a pharmaceutical company focused on developing and commercializing innovative treatments for addiction and mental health disorders. The company operates primarily in the healthcare industry, providing solutions that address unmet medical needs in these areas.
Average Trading Volume: 14,963
Current Market Cap: SEK514.4M
For an in-depth examination of ORX stock, go to TipRanks’ Stock Analysis page.